NBCD A/S: Financial statements 2013
CVR: 30582462
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
NBCD A/S (CVR 30582462) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -3,384,452 and a net result of DKK -11,792,867. Equity in the 2013 report amounted to DKK -22,863,732.
- Gross Profit
- DKK -3,384,452
- Profit/Loss
- DKK -11,792,867
- Equity
- DKK -22,863,732
- Total Assets
- DKK 35,999,769
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2013 | - | -3.4 mio. | -11.8 mio. | -22.9 mio. | - |
| 2012 | - | - | - | 500 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of October 1, 2013, BAKER TILLY DENMARK GODKENDT REVISIONSAKTIESELSKAB has been appointed auditor of NBCD A/S.
As of October 1, 2013, ATHOS STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of NBCD A/S.
NBCD A/S has published its annual report for 2012.
About NBCD A/S
NBCD A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2007. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NORDIC BIOSCIENCE CLINICAL DEVELOPMENT A/S and NORDIC BIOSCIENCE PROJECT 2 A/S. The management consists of Jeppe Ragnar Andersen and Mark Høgh Gandrup. The board consists of Pierre Khaitrine (chair), Jeppe Ragnar Andersen and José Ignacio Pfeifer. The company is owned by Sanos Holding A/S. The company has 24 employees (2018). In 2025, the company reported a gross profit of DKK 31,583,144 and a net result of DKK 9,222,892 compared with DKK 52,621,101 the year before. Equity in the 2025 report amounted to DKK 136,144,994.